Abstract
A series of N-(4-phenyl-1, 3-thiazol-2-yl)-N'- phenylureas (5a-z) was synthesized from 2-amino-4-substituted phenylthiazoles and phenylisocyanates. The newly synthesized compounds were characterized by IR, 1H NMR and Mass spectral data. All the twenty six N-(4-phenyl-1, 3-thiazol-2-yl)-N'-phenylurea derivatives were screened for antiinflammatory activity by following carrageenan induced rat paw edema method. Among the compounds screened, N-[4- (4-methoxy phenyl)-1, 3-thiazol-2-yl)-N'-phenylurea and N-[4-(4-methoxy phenyl-1, 3-thiazol-2-yl)-N'-(4-bromophenyl) urea were found to be more potent. The molecular docking interaction of aforementioned urea compounds revealed the traditional type II p38 kinase inhibitor’s interactions in the DFG out active site.
Keywords: Anti-inflammatory, 2-amino-4-phenyl thiazole, molecular docking, N-(4-phenyl-1, 3-thiazol-2-yl)-N'-phenyl urea, p38 kinase.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Synthesis, Characterization and Anti-inflammatory Activity of N-(4- phenyl-1, 3-thiazol-2-yl)-N'-phenylureas
Volume: 13 Issue: 2
Author(s): Aneesa Fatima, Ravindra Kulkarni, Bhagavanraju Mantripagada, Asief Mohammed, Anusaya Birajdar and V.M. Chandrasheskar
Affiliation:
Keywords: Anti-inflammatory, 2-amino-4-phenyl thiazole, molecular docking, N-(4-phenyl-1, 3-thiazol-2-yl)-N'-phenyl urea, p38 kinase.
Abstract: A series of N-(4-phenyl-1, 3-thiazol-2-yl)-N'- phenylureas (5a-z) was synthesized from 2-amino-4-substituted phenylthiazoles and phenylisocyanates. The newly synthesized compounds were characterized by IR, 1H NMR and Mass spectral data. All the twenty six N-(4-phenyl-1, 3-thiazol-2-yl)-N'-phenylurea derivatives were screened for antiinflammatory activity by following carrageenan induced rat paw edema method. Among the compounds screened, N-[4- (4-methoxy phenyl)-1, 3-thiazol-2-yl)-N'-phenylurea and N-[4-(4-methoxy phenyl-1, 3-thiazol-2-yl)-N'-(4-bromophenyl) urea were found to be more potent. The molecular docking interaction of aforementioned urea compounds revealed the traditional type II p38 kinase inhibitor’s interactions in the DFG out active site.
Export Options
About this article
Cite this article as:
Fatima Aneesa, Kulkarni Ravindra, Mantripagada Bhagavanraju, Mohammed Asief, Birajdar Anusaya and Chandrasheskar V.M., Synthesis, Characterization and Anti-inflammatory Activity of N-(4- phenyl-1, 3-thiazol-2-yl)-N'-phenylureas, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2014; 13 (2) . https://dx.doi.org/10.2174/1871523013666140820154843
DOI https://dx.doi.org/10.2174/1871523013666140820154843 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HSV Amplicon Vectors for Cancer Therapy
Current Gene Therapy Modification of Chemokine Pathways and Immune Cell Infiltration as a Novel Therapeutic Approach in Liver Inflammation and Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Efficient Expression and Purification of Recombinant Therapeutic Protein Candidates, Human Midkine and Pleiotrophin
Current Pharmaceutical Biotechnology Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?
Current Cancer Drug Targets Non-Specific Microbicide Product Development: Then and Now
Current HIV Research Dietary Interventions in Children with Autism Spectrum Disorders - An Updated Review of the Research Evidence
Current Clinical Pharmacology Patterns of Expression of Viral and Cytokine Gene Transcripts During Mouse Polyoma Virus Infection
Combinatorial Chemistry & High Throughput Screening Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives
Current Medicinal Chemistry No Zinc Deficiency But a Putative Immunosuppressive Role for Labile Zn in Patients with Systemic Autoimmune Disease
Current Rheumatology Reviews Reactive Intermediates and the Pathogenesis of Adverse Drug Reactions: The Toxicology Perspective
Current Drug Metabolism Dietary Intervention for Allergic Disease
Current Pharmaceutical Design Transcriptional Regulation of CYP2C19 and its Role in Altered Enzyme Activity
Current Drug Metabolism Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia The Hyperforin Derivative IDN5706 Occludes Spatial Memory Impairments and Neuropathological Changes in a Double Transgenic Alzheimers Mouse Model
Current Alzheimer Research Safety and Efficacy of Immune Checkpoint Inhibitors in Children and Young Adults with Haematological Malignancies: Review and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry A Hypothesis for Regenerative Therapy for Neuronal Disease: Stem Cells within Artificial Niche
Current Signal Transduction Therapy Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry Inflammation in Arthropods
Current Pharmaceutical Design The Neuropharmacological Effects of Magnolol and Honokiol: A Review of Signal Pathways and Molecular Mechanisms
Current Molecular Pharmacology Revision on Renal Sympathetic Ablation in the Treatment of Resistant Hypertension
Current Hypertension Reviews